Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.59
-4.8%
$1.44
$0.87
$6.78
$158.99M0.74827,907 shs299,435 shs
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
$3.70
-1.3%
$3.06
$2.38
$5.54
$221.56M-0.16336,430 shs376,222 shs
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$3.63
-0.7%
$3.77
$3.36
$12.22
$145.15M1.114,493 shs408 shs
Mural Oncology PLC stock logo
MURA
Mural Oncology
$2.50
+0.4%
$2.57
$0.95
$4.74
$43.17M3.031.29 million shs99,378 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
0.00%-1.24%+8.90%+72.81%-72.73%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
0.00%+8.19%+33.09%+23.75%+34.55%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
0.00%+2.23%-3.33%-8.69%-44.40%
Mural Oncology PLC stock logo
MURA
Mural Oncology
0.00%+2.46%+1.21%-7.41%-28.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alector, Inc. stock logo
ALEC
Alector
3.5783 of 5 stars
3.12.00.04.51.12.50.0
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
2.0362 of 5 stars
3.51.00.00.03.31.70.0
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
2.9703 of 5 stars
3.85.00.00.00.00.00.6
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.8139 of 5 stars
3.35.00.00.00.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.14
Hold$4.00151.57% Upside
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
3.00
Buy$9.00143.24% Upside
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
3.50
Strong Buy$12.00231.03% Upside
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.50
Moderate Buy$12.00380.00% Upside

Current Analyst Ratings Breakdown

Latest MURA, ELDN, MOLN, and ALEC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$9.00
5/9/2025
Alector, Inc. stock logo
ALEC
Alector
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$88.34M1.80N/AN/A$1.29 per share1.23
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/A$1.98 per shareN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$5.65M25.91N/AN/A$3.99 per share0.91
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/AN/AN/AN/A$8.22 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$61.39M-$1.92N/AN/AN/AN/A-42.20%-38.12%8/25/2025 (Estimated)
Mural Oncology PLC stock logo
MURA
Mural Oncology
-$128.51M-$7.67N/AN/AN/AN/A-83.39%-70.70%8/12/2025 (Estimated)

Latest MURA, ELDN, MOLN, and ALEC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025N/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
-$1.13N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Alector, Inc. stock logo
ALEC
Alector
-$0.45N/AN/AN/A$2.76 millionN/A
5/15/2025Q1 2025
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.3855-$0.50-$0.1145-$0.50N/AN/A
5/14/2025Q1 2025
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
-$0.28-$0.08+$0.20-$0.08N/AN/A
5/14/2025Q1 2025
Mural Oncology PLC stock logo
MURA
Mural Oncology
-$2.12-$1.93+$0.19-$1.93N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/AN/AN/AN/AN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.10
3.34
3.34
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
N/A
13.90
13.91
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/A
15.28
15.28
Mural Oncology PLC stock logo
MURA
Mural Oncology
N/A
5.08
5.08

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
56.77%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
26.55%
Mural Oncology PLC stock logo
MURA
Mural Oncology
80.21%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
9.10%
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
12.30%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
5.93%
Mural Oncology PLC stock logo
MURA
Mural Oncology
2.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
27099.99 million90.89 millionOptionable
Eledon Pharmaceuticals, Inc. stock logo
ELDN
Eledon Pharmaceuticals
1059.88 million52.52 millionOptionable
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
18040.38 million37.98 millionNot Optionable
Mural Oncology PLC stock logo
MURA
Mural Oncology
11917.27 million16.89 millionOptionable

Recent News About These Companies

Minneapolis muralist honors Tuskegee airmen
Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
BlackRock discloses 1.64% stake in Mural Oncology
Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
BlackRock discloses 1.39% stake in Mural Oncology
BlackRock discloses stake in Mural Oncology plc
BlackRock discloses stake in Mural Oncology
FORM 8.1(a) & (b) - Mural Oncology plc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alector stock logo

Alector NASDAQ:ALEC

$1.59 -0.08 (-4.79%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.58 -0.01 (-0.31%)
As of 07/18/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Eledon Pharmaceuticals stock logo

Eledon Pharmaceuticals NASDAQ:ELDN

$3.70 -0.05 (-1.33%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.82 +0.12 (+3.35%)
As of 07/18/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$3.62 -0.03 (-0.68%)
Closing price 07/18/2025 03:27 PM Eastern
Extended Trading
$3.62 0.00 (0.00%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Mural Oncology stock logo

Mural Oncology NASDAQ:MURA

$2.50 +0.01 (+0.40%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.50 0.00 (-0.20%)
As of 07/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.